A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis

被引：14
|
作者：
Hansel, K. [1 ]
Zangrilli, A. [2 ]
Bianchi, L. [1 ,2 ]
Peris, K. [3 ]
Chiricozzi, A. [3 ]
Offidani, A. [4 ]
Diotallevi, F. [4 ]
Fargnoli, M. C. [5 ]
Esposito, M. [5 ]
Amerio, P. [6 ]
Gualdi, G. [6 ]
Bianchi, L. [1 ,2 ]
Stingeni, L. [1 ]
机构：
[1] Univ Perugia, Dept Med & Surg, Dermatol Sect, Perugia, Italy
[2] Univ Roma Tor Vergata, Dept Syst Med, Policlin Tor Vergata, Dermatol Unit, Rome, Italy
[3] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy
[4] Polytech Univ Marche Reg, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy
[5] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Dermatol, Laquila, Italy
[6] Univ G dAnnunzio, Dermatol Clin, Dept Med & Aging Sci, Chieti, Italy
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 02期
关键词：
D O I：
10.1111/jdv.17656
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E111 / E113
页数：3
相关论文
共 50 条
  • [21] Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
    Gonulal, Melis
    Balci, Didem Didar
    Ozturkcan, Serap
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3653 - 3659
  • [22] Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    [J]. DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [23] A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis
    Michelucci, Alessandra
    Margiotta, Flavia Manzo
    Panduri, Salvatore
    Tonini, Annalisa
    Romanelli, Marco
    Morganti, Riccardo
    Janowska, Agata
    Dini, Valentina
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (04)
  • [24] Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period
    Trovato, Emanuele
    Cortonesi, Giulio
    Orsini, Corinne
    Capalbo, Eugenio
    Cinotti, Elisa
    Rubegni, Pietro
    Cartocci, Alessandra
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [25] Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
    Megna, Matteo
    Potestio, Luca
    Ruggiero, Angelo
    Camela, Elisa
    Fabbrocini, Gabriella
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (05) : 2560 - 2564
  • [26] Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
    Martora, Fabrizio
    Marasca, Claudio
    Cacciapuoti, Sara
    Fariello, Federica
    Potestio, Luca
    Battista, Teresa
    Scalvenzi, Massimiliano
    Megna, Matteo
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2024, 17 : 159 - 166
  • [27] Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study
    Dragotto, Martina
    Capalbo, Eugenio
    Cartocci, Alessandra
    Manzo Margiotta, Flavia
    Michelucci, Alessandra
    Rosi, Elia
    Ricceri, Federica
    Simoni, Barbara
    Savarese, Imma
    Milanesi, Nicola
    Rossari, Susanna
    Magnano, Michela
    Romanelli, Marco
    Rubegni, Pietro
    Prignano, Francesca
    Di Cesare, Antonella
    Panduri, Salvatore
    Pescitelli, Leonardo
    Trovato, Emanuele
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (08) : E1075 - E1077
  • [28] Real-life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study
    Giacomo, Caldarola
    Emanuele, Trovato
    Martina, Burlando
    Eugenio, Capalbo
    Federico, Diotallevi
    Viviana, Lora
    Maria, Pinto Lorenzo
    Ruslana, Gaeta Shumak
    Thais, Fastame Maria
    Marco, Mariani
    Elena, Campione
    Annamaria, Offidani
    Aurora, Parodi
    Francesca, Prignano
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (04) : e92 - e96
  • [29] Improvement of self-administration experience with a new injection device: Real-life experience with risankizumab in patients with psoriasis
    Brunasso, Alexandra Maria Giovanna
    Salvi, Ilaria
    Sorbara, Stefania
    Muracchioli, Andrea
    De Col, Elena
    Baldari, Manuela
    Parodi, Aurora
    Cozzani, Emanuele
    Burlando, Martina
    [J]. SKIN RESEARCH AND TECHNOLOGY, 2024, 30 (08)
  • [30] Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period
    Matteo Megna
    Eleonora Cinelli
    Lucia Gallo
    Elisa Camela
    Angelo Ruggiero
    Gabriella Fabbrocini
    [J]. Archives of Dermatological Research, 2022, 314 : 619 - 623
12345